Search Results

Samus Therapeutics, Inc. (“Samus Therapeutics” or the “Company”), today announced the first patient was dosed in the multicenter Phase 1b study of icapamespib in patients with recurrent malignant glioma.

Samus Therapeutics, Inc. (“Samus Therapeutics” or the “Company”), today announced the publication on November 25, 2021 of an open article in Communications Biology about how epichaperome inhibition by zelavespib (PU-H71) can increase the vulnerability of cancer cells to traditionally poor performing therapeutics.

Clearance of the IND allows Samus to proceed with a Phase Ib trial to assess the safety, tolerability and pharmacokinetics of PU-AD in a small group of patients with recurrent malignant glioma.

Samus Therapeutics, Inc., a privately held, Boston-based biopharmaceutical company developing epichaperome inhibitors to treat central nervous system diseases and hematologic malignancies, announced the publication of an open article in Nature Communications.

Samus Therapeutics, Inc. (“Samus” or the “Company”), a privately held, Boston -based, biopharmaceutical company developing epichaperome inhibitors to intervene in pathological processes and initiate the degradation of disease-associated proteins, today announced that Dick Bagley , President and Interim Chief Executive Officer,

Samus Therapeutics, Inc., a privately held, Boston-based biopharmaceutical company developing epichaperome inhibitors to treat CNS diseases and hematologic malignancies, announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application to develop PU-AD for the treatment of recurrent malignant glioma.

Samus Therapeutics, Inc. (“Samus” or the “Company”), a privately held, Boston-based, biopharmaceutical company developing epichaperome inhibitors to intervene in pathological processes and initiate the degradation of disease-associated proteins, today announced the presentation of initial Phase 1 data for Alzheimer’s Disease at the 12th annual Clinical Trials in Alzheimer’s Disease (CTAD) Congress,

Samus Therapeutics, Inc., a privately held, biopharmaceutical company developing small molecule epichaperome inhibitors, announced the presentation of safety and pharmacokinetic data from the Company’s recently completed PU-AD healthy volunteer Phase 1 study at the Alzheimer’s Association International Conference.

Samus Therapeutics, Inc. (“Samus” or the “Company”), today announced a poster presentation addressing the Company’s Phase 1 study evaluating orally administered PU-H71 with ruxolitinib in patients with myelofibrosis no longer fully responsive to orally administered ruxolitinib.